1016340-64-9
Chemical Structure
Z57346765
- CAS No.: 1016340-64-9
- Formula:C17H18N4O
- Molecular Weight:294.36
IUPAC Name: 2-((2-(p-tolylamino)quinazolin-4-yl)amino)ethan-1-ol
InChIKey: GJTXWNCGKNQIFN-UHFFFAOYSA-N
SMILES: OCCNC1=C2C=CC=CC2=NC(NC3=CC=C(C)C=C3)=N1
Biological Activity: Z57346765 is an inhibitor that targets the ADP-binding pocket of PGK1, with a Kd of 20.9 μM for human PGK1, and exhibits anticancer activity. Z57346765 reduces the activity of the metabolic enzyme PGK1 during glycolysis, regulates lipid peroxidation and cancer cell proliferation, and promotes lipid peroxidation in cervical cancer cells. Z57346765 inhibits the proliferation of cervical cancer and clear cell renal cell carcinoma cells in xenograft mouse models, and induces the expression of genes associated with cell metabolism, DNA replication and cell cycle. Z57346765 is used in research related to cervical cancer, clear cell renal cell carcinoma and breast cancer[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Z57346765 | 99.85% | Z57346765 is an inhibitor that targets the ADP-binding pocket of PGK1, with a Kd of 20.9 μM for human PGK1, and exhibits anticancer activity. Z57346765 reduces the activity of the metabolic enzyme PGK1 during glycolysis, regulates lipid peroxidation and cancer cell proliferation, and promotes lipid peroxidation in cervical cancer cells. Z57346765 inhibits the proliferation of cervical cancer and clear cell renal cell carcinoma cells in xenograft mouse models, and induces the expression of genes associated with cell metabolism, DNA replication and cell cycle. Z57346765 is used in research related to cervical cancer, clear cell renal cell carcinoma and breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Zhang B, et al. Downregulation of PGK1 promotes lipid peroxidation and suppresses proliferation in cervical cancer revealed by liquid-liquid phase separation-related gene signature. BMC Cancer. 2025;25(1):1269. Published 2025 Aug 5. [Content Brief]
- [2]. He Y, et al. Novel inhibitors targeting the PGK1 metabolic enzyme in glycolysis exhibit effective antitumor activity against kidney renal clear cell carcinoma in vitro and in vivo. Eur J Med Chem. 2024;267:116209. [Content Brief]
- [3]. Chen X, et al. Identification of a Potential PGK1 Inhibitor with the Suppression of Breast Cancer Cells Using Virtual Screening and Molecular Docking. Pharmaceuticals (Basel). 2024;17(12):1636. Published 2024 Dec 5. [Content Brief]
Keywords
